Introduction {#s0001}
============

Nascent transcripts produced by RNA polymerases universally carry a 5′ triphosphate (5′ppp). Processed RNA molecules, such as rRNAs and tRNAs, generated from precursors whose 5′ segments were removed by nucleolytic cleavage, carry a 5′ monophosphate (5′p). In several types of cellular and viral RNAs, the 5′ end is further modified enzymatically, by a variety of modification enzymes, to introduce various chemical structures that are collectively dubbed as the "5′ caps". This cap is absent in bacterial and archaeal transcripts.

The most typical and widely studied cap modification comprises the addition of an *N*^7^-methylguanosine (m^7^G) linked via an inverted 5′--5′ triphosphate bridge to the 5′-terminal nucleoside of the transcript.[@cit0001] This structure termed cap0 is a characteristic feature of transcripts that are produced by RNA polymerase II, such as messenger RNAs (mRNAs) of all eukaryotic organisms and many viral RNAs. It is typically introduced in sequential steps: (1) hydrolysis of 5′ γ-phosphate of a nascent pre-mRNA to generate a 5′ diphosphate mRNA end; (2) transfer of a guanine monophosphate nucleoside; and (3) methylation of the guanine at the *N*^7^ position. The cap0 structure was shown to be essential for cell growth of *Saccharomyces cerevisiae*[@cit0002] and survival of mammalian cells;[@cit0003] it is critical for mRNA interactions with many nuclear and cytoplasmic proteins and has multiple important roles in gene expression, including enhancement of RNA stability, splicing, nucleocytoplasmic transport, and translation initiation.[@cit0004] Enzymes responsible for cap0 formation have been well characterized in many organisms and viruses.

In many instances, m^7^G-capped RNAs are modified further, in particular by additional methylation steps at the cap0 guanosine or methylation of the first few transcribed nucleoside residues. For instance, the cap0 guanosine is modified by addition of 2 methyl groups at the *N*^2^ position, yielding a trimethylguanosine (m^2,2,7^G or TMG) cap, in some small nuclear RNAs (snRNAs) and nucleolar RNAs (snoRNAs) required for pre-mRNA splicing (e.g., U1, U2, U4, and U5), pre-rRNA processing (U3 and U8), and telomere addition (telomerase RNA), as well as in several selenoprotein mRNAs.[@cit0006]

In higher eukaryotes, the 5′ ends of mRNA and snRNA are modified further by ribose 2′-*O*-methylation on the first and second transcribed nucleosides, yielding cap1 and cap2 modifications, respectively.[@cit0007] In humans, cap0 and cap1 methylations are found on all mRNA molecules, while about half of the capped and polyadenylated RNA molecules contain a 2′-*O*-methylated residue at the second transcribed position.[@cit0008] The U1, U2, U4, and U5 snRNAs are methylated at both the first 2 positions.[@cit0009] Cap1 and cap2 methylations in U2 snRNA are required for the formation of spliceosomal E-complex and, as a consequence, for efficient pre-mRNA splicing.[@cit0010] In some organisms, such as in Trypanosomes, as many as 4 first residues of the nascent transcript undergo ribose methylation, to generate the cap4 structure.[@cit0011] These additional methylation steps are often important for RNA processing, translation and stability, although their role has not been fully elucidated.

Alternative capping pathways have been invented by certain viruses. For instance, in Alphaviruses, the precursor of cap0 is first methylated to a m^7^G triphosphate and only then connected to the 5′ end of the RNA.[@cit0012] Nonsegmented negative-sense (nsNS) RNA viruses have evolved a different mechanism for mRNA cap formation in that the guanylyltransferase transfers GDP rather than GMP onto the 5′ end of the RNA and the resulting cap structure is first monomethylated on the ribose of the first transcribed residue (yielding GpppAm structure), and only later the guanosine is methylated to m^7^G.[@cit0013]

In addition to ribose 2′-*O*-methylation, base moieties of the first transcribed nucleosides may be methylated, thereby increasing the catalog of 5′ cap structures. In particular, the first adenine nucleoside of the transcript is often methylated at the *N*^6^ position.[@cit0016] In Trypanosomes, the fourth uridine residue is also methylated at the *N*^3^ position. The role of these base methylations is unclear, and the enzymes responsible for these modifications remain to be characterized.

Some small RNAs, including mammalian U6 and 7SK, mouse B2, and plant U3, present a completely different 5′ cap structure, which is chemically minimalistic compared to the elaborate guanosine cap. This alternative cap is generated by methylation of a γ-phosphate oxygen at the unprocessed 5′ end of the primary transcript.[@cit0017]
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In this review, we discuss cellular and viral methyltransferases involved in 5′ cap RNA biosynthesis, with emphasis on the sequence structure relationships in the light of the experimentally determined structures of enzymes complexed with their ligands. We focus on comparison of enzymes with similar activities that generate products with chemically similar structures.

Throughout the article, we follow the nomenclature of cap modifying enzymes and their products commonly used in the literature. We use terms "capX methylation" and "capX methyltransferase" (where X is a number) to refer to some enzymatic activity or its product at a particular position X. On the other hand, the term "capX structure" is used to refer to a fully modified cap structure. For instance "cap2 structure" indicates a cap methylated on the inverted guanosine and the first 2 ribose sugars in the nucleotide sequence; i.e., m^7^GpppN~1~mN~2~m. It should be emphasized that some of the cap methyltranserases discussed here have not yet been fully characterized and it cannot be ruled out that they act at multiple positions.

Cap-specific m^7^G methyltransferases {#s0001-0001}
-------------------------------------

Cellular and viral RNA cap guanine-*N*^7^-methyltrasferases methylate RNA with the GpppN 5′ terminus to form an m^7^GpppN (cap0) structure. Eukaryotic enzymes catalyze this reaction in the nucleus. Many viruses, however, replicate in the cytoplasm of their eukaryotic host, and the cellular capping machinery is not accessible for their RNAs; hence, these viruses have evolved their own capping enzymes to form a cap structure that can be recognized by the cellular translation machinery for gene expression. Examples include Flaviviridae, Nidovirales, Mononegavirales and Poxviridae (reviewed in ref. 12). While the cellular and viral mRNA capping apparatus is functionally similar, the enzyme organization differs greatly across evolution.

The Abd1 protein from *Saccharomyces cerevisiae* is a monofunctional cap0 methyltransferase, and biochemically has been one of the best studied methyltransferases involved in cap structure biosynthesis.[@cit0002] Its enzymatic activity is critical for yeast cell growth and the gene *ABD1* that encodes the Abd1 protein is essential. Abd1 is a founding member of a protein family that is strongly conserved in eukaryotes as well as in viruses.[@cit0024] The crystal structure of *S. cerevisiae* Abd1 itself could not be determined, but eventually it was solved for its homolog, the Ecm1 protein from *E. cuniculi* ([**Fig. 2**](#f0002){ref-type="fig"}).[@cit0025] Purified Ecm1 is a monomeric protein that catalyzes methyl transfer to GpppRNA to form cap0, but also to free mononucleotides GTP, GDP or dGTP (deoxy-GTP). The methyltransferase domain in Ecm1, and by inference also in other homologous cap0 methyltransferases, exhibits the RFM fold with a characteristic insertion that forms a characteristic β-meander structure involved in the formation of the cap-binding site. This insertion is common between methyltransferases that methylate G to m^7^G in the RNA cap, and methyltransferases that N-methylate the amino acid glycine. This relationship between 2 different types of methyltransferases, as well as the cap0 methyltransferase structure, were correctly predicted using bioinformatics[@cit0024] before the first structure of the cap0 methyltransferase was determined. Figure 2.**Crystal structure of the cap0 methyltransferase from *Encephalitozoon cuniculi***. A stick representation of the ligands bound to cap0 methyltransferase. The guanosine cap analog position was defined based on the structure deposited as 1RI2 in the PDB, and the methyl group donor position was depicted based on the structure deposited as 1RI4 in the PDB. Secondary structure elements that correspond to elements of the conserved RFM core are labeled. Secondary structure elements outside of the conserved core are not labeled.

In the human capping system, the cap0 methyltransferase (RNMT) consists of a catalytic subunit related to Abd1 and an obligate activating subunit, RAM (RNMT-activating miniprotein).[@cit0026] The C-terminal catalytic domain of RNMT has essentially the same structure as Abd1. RNMT also has an N-terminal domain that is conserved in mammals, but not required for catalytic activity. However, it contains 2 nuclear localization signal motifs and the nuclear localization of RNMT is essential for cell viability. The cap0 methyltransferases, members of the above-mentioned family, were also identified and chartacterized in other eukaryotes, including TbCmt1 in *Trypanosoma brucei*, for example.[@cit0027]

As mentioned above, the viral cap0 methyltransferases possess a catalytic domain that is closely related to the eukaryotic cap0 methyltransferases, but it often functions in the context of other domains. For instance, the vaccinia virus possesses an enzyme that is composed of D1 and D12 polypeptides that execute all 3 steps in cap0 biosynthesis. The D1 subunit contains triphosphatase and guanylyltransferase activities in the N-terminal domain, and a cap0 methyltransferase domain that forms a heterodimer with the D12 subunit.[@cit0028] The methyltransferase active site is located entirely in the D1 subunit and has a weak cap0 modification activity that is stimulated allosterically by D12.[@cit0030] Interestingly, the D12 structure resembles a degenerate cap 2′-*O*-ribose methyltransferase domain (see below), but it lacks a proper SAM binding site and does not show any methyltransferase activity on its own.[@cit0033]

In the SARS-coronavirus, a nonstructural protein 14 (nsp14) was initially identified as an exoribonuclease (and termed ExoN). Later, it was shown that it also exhibits cap0 methyltransferase activity. Analysis of protein variants with substitutions of conserved residues in the ExoN (N-terminal) and methyltransferase (C-terminal) domains revealed that both active sites are functionally distinct; however, the integrity of the ExoN domain turned out to be essential for the function of the cap0 methyltransferase domain.[@cit0034] Nsp14 shows little sequence similarity to known methyltransferases; however, its structure has not been determined experimentally, hence its phylogenetic relationships to other enzymes remain unclear.

Cap-specific 2′-*O*-ribose methyltransferases {#s0001-0002}
---------------------------------------------

A poxvirus cap1-forming enzyme (VP39 protein from vaccinia virus), was the first methyltransferase involved in the cap structure formation, for which a crystal structure was determined[@cit0035] and also the first one for which a structure of a ternary complex of an enzyme with the cofactor and RNA substrate was determined.[@cit0036] It has become one of the best studied members of a large family of methyltransferases that act on the 2′-OH-ribose group in RNA, which includes also enzymes such as RrmJ and fibrillarin.[@cit0037] Although they share little sequence identity with each other, these 2′-*O*-ribose methyltransferases are characterized by the presence of a conserved tertiary fold characteristic for all RFM enzymes and a conserved K-D-K catalytic triad between the methyl group donor binding site, and the cap binding site. VP39 is a single-domain protein with additional structural elements at both the N- and C-termini, which wrap around the RFM core and form a binding pocket for the cap. In the ternary complex, the m^7^G base of the cap is bound sandwiched between 2 aromatic side chains, and oriented in such a way that the Hoogsteen edge modified by addition of the methyl group on *N*^7^ faces the protein, thus explaining the ability of VP39 to sense the methylation status of the substrate, which is the basis of its preference for substrates that already have an *N*^7^-methylated cap.

In humans, cap1 formation is catalyzed by the CMTr1 enzyme.[@cit0038] It is composed of several domains, including the N-terminal catalytic RMF domain with a conserved K-D-K triad characteristic for 2′-*O*-ribose methyltransferases and a guanylyltransferase-like domain that lacks catalytic residues.[@cit0039] The N-terminal domain of CMTr1 shares a global architecture with the VP39 protein and is sufficient for cap1 activity in vitro. Interestingly, while the cofactor-binding sites, active sites, and the sites of binding of the nascent RNA chain exhibits similarities with the VP39 and CMTr1 enzymes (and likewise the conformations of the respective ligands), their cap-binding sites exhibit large differences in the shape of the m^7^G-binding pocket. As a result, CMTr1 binds m^7^G in a different way, in which the sugar edge of the cap guanosine faces the protein, and the methyl group on N7 faces the solvent ([**Fig. 3**](#f0003){ref-type="fig"}). These structural differences explain why CMTr1 is relatively insensitive to the absence of cap0 methylation and therefore is able to act, at least in vitro, on substrates with unmethylated guanosine. Figure 3.**Comparison of the crystal structures of 2**′**-*O*-ribose methyltransferases**. (**A**) Superimposition of the catalytic domain of human CMTr1 methyltransferase (colored black; PDB ID: 4N48), VP39 methyltransferase from the vaccinia virus (colored dark gray; PDB ID: 1AV6) and the NS5 protein from the Wesselsbron virus (colored bright gray; PDB ID: 3EMB). The ligands are shown in stick representation and they are colored corresponding to the hue used for protein molecules representation. Secondary structure elements that correspond to elements of the conserved RFM core are labeled (α1, β6, and β7 are hidden behind other elements and their labels have been omitted). Secondary structure elements outside of the conserved core are not labeled. (**B**) The capped oligoribonucleotide (m^7^GpppGAUC) located in its binding pocket on the surface of human CMTr1 MTase is shown in stick representation. The side chains of Phe206 and Glu373 that correspond to stacking residues in viral methyltransferases and the 3 catalytic residues are also displayed. (**C**) The crystal structure of the VP39 methyltransferase from vaccinia virus in complex with m^7^GpppGAAAAA (shown in stick representation). The methylated guanine ring is stacked by 2 aromatic rings of Tyr22 and Phe180. (**D**) A stick representation of the cap0 structure analog---m^7^GpppG bound by NS5 flaviviral 2′-*O*-ribose methyltransferase.

Proteins with cap1 methyltransferase activities were also characterized in the alfalfa looper moth *Autographa californica* nucleopolyhedrovirus (orf69[@cit0040]) and in *T. brucei* (TbMTr1[@cit0041]). Both of these enzymes are relatively closely related to the human CMTr1 enzyme.

In the SARS virus, cap1 methylation is catalyzed by a complex comprised of 2 partners: the nsp16 protein that is clearly related to the above-mentioned cap1 methyltransferases, but is inactive on its own, and a small regulatory protein nsp10 that is required for nsp16 to bind both the SAM methyl group donor and the RNA substrate. The crystal structure of the snp10-nsp16 complex showed that, in nsp16, the SAM-binding region is partially degenerated compared to "partner-independent" ribose methyltransferases, and nsp10 stabilizes the SAM binding pocket and extends the RNA-binding groove of nsp16.[@cit0043]

Apart from the enzymes responsible for cap1 methylation, methyltransferases have been characterized that act on additional residues in the nascent RNA chain. Many eukaryotic organisms possess a 2′-*O*-ribose methyltransferase that methylates the 2^nd^ residue in mRNA and in other RNA molecules. The cap2 methyltransferase has been characterized in *T. brucei* (TbMTr2[@cit0044]) and in humans (CMTr2[@cit0046]). Interestingly, while CMTr2 appears to be closely related to its human paralog CMTr1 as well as to TbMTr1, TbMTr2 is more closely related to the vaccinia virus cap1 methyltransferase.[@cit0044] In trypanosomes, a third 2′-*O*-ribose cap methyltransferase was identified and termed TbMTr3, which is responsible for the methylation of the third residue of the cap and is required for the methylation of the fourth residue.[@cit0047] TbMTr3 is a close relative of TbMTr2 and of VP39, and is only remotely related to other eukaryotic cap 2′-*O*-ribose methyltransferases, which suggests that trypanosomes acquired enzymes for "additional" methylation by adapting proteins from viruses. A phylogenetic study of 2′-*O*-ribose methyltransferases revealed that the relationships between cellular and viral enzymes are quite complex, and that these proteins can vary greatly in number even in closely-related organisms. Furthermore, alveolate species were identified that possessed as many as 4 2′-*O*-ribose methyltransferases, suggesting that certain enzymes of this group may act with different substrate specificities or that new cap structures with additional methylation sites remain to be discovered.[@cit0046]

Proteins with cap0 and cap1 methyltransferase activities {#s0001-0003}
--------------------------------------------------------

A number of viral proteins were reported to possess both cap0 and cap1 methyltransferase activities. In most of them, this is due to the presence of multiple domains. For instance, in the human reovirus (a virus with a dsRNA genome), the cap structure formation is catalyzed by a large multidomain protein lambda 2, which in turn is a part of the reovirus core: an assembly with a relative molecular mass of 52 MDa that synthesizes, modifies and exports viral mRNA. The structure of the human reovirus core has been solved at low resolution, revealing a series of domains that include a putative guanylyltransferase domain and 2 putative methyltransferase (RFM) domains.[@cit0049] It has been suggested that the order of the domains in the lambda 2 protein corresponds to the order of the capping reactions: guanosine transfer followed by cap0 and cap1 methylation. However, comparison of domain structures suggested that the functional assignments may be different, as the RFM domain 1 shared a putative active site with the corresponding structurally characterized 2′-*O*-ribose methyltransferases, including the cap1 methyltransferase, whereas the RFM domain 2 exhibited structural similarity to the cap0 methyltransferases.[@cit0050] It should be noted that the putative cap1 methyltransferase domain of reovirus exhibits a similar cap-binding platform formed by N- and C-terminal extensions, as in VP39 and human CMTr1 enzymes; however, its putative m^7^G-binding site is more open.

In bluetongue virus, another member of the reoviruses, the structure of the VP4 protein revealed a multi-domain protein with an N-terminal guanylyltransferase domain and 2 RFM domains, of which one was inserted into another. The inserted RFM domain exhibited clear similarities to the cap1 methyltransferases and in 3 crystal forms had GpppG, m^7^GDP, or GTP bound in the position of the cap-binding site, while the other RFM domain exhibited low but significant similarity to known cap0 methyltransferase structures.[@cit0051]

In the non-segmented, negative-sense single-stranded RNA viruses \[order Mononegavirales (MNV)\] that include pathogens such as respiratory syncytial virus, measles, mumps, rabies, parainfluenza, vesicular stomatitis virus (VSV), and Marburg and Ebola viruses, one of the common components of the viral ribonucleoprotein core is the large (L) protein, which encodes multiple functions such as the RNA-dependent RNA polymerase and activities responsible for mRNA capping, cap0 and cap1 methylation, poly(A) polymerase and protein kinase.[@cit0052] Using bioinformatics methods, we and others predicted that the C-terminal region of that protein (conserved region VI) encodes a domain homologous to 2′-*O*-ribose methyltransferases and is likely to function as a cap1 methyltransferase.[@cit0054] Later it was found that, in VSV, this region is essential not only for cap1, but also for cap0 methyltransferase activity and that the same SAM-binding site and part of the K-D-K triad is used for both reactions.[@cit0015] The structural basis of this phenomenon remains to be determined.

In Flaviviruses (positive-sense, single-stranded RNA viruses), an RFM domain with a similar dual methyltransferase function was identified. In a non-structural protein 5, the N-terminus was first unambiguously characterized as a cap1 (2′-*O*-ribose) methyltransferase. Later, it was shown that this domain takes part also in cap0 (m^7^G) methylation using the same SAM-binding site during cap synthesis.[@cit0057] Interestingly, in these viruses, the order of methylation is different than in Mononegavirales, as cap0 methylation precedes cap1 methylation. Several structures were determined for the flavivirus cap methyltransferases known or predicted to be bifunctional, including Dengue,[@cit0059] West Nile,[@cit0060] Wesselbron,[@cit0061] Meaban,[@cit0062] and Murray Valley encephalitis[@cit0063] viruses and they all revealed high similarity to the cap1 methyltransferases, and little if any similarity to the classical cap0 methyltransferases. It should be noted that these methyltransferases share a similar cap-binding platform structure with VP39 and human CMTr1 enzymes (a platform formed by N- and C-terminal extensions); however, the orientation of the bound guanosine residue suggests that their mode of cap-recognition is different from both poxvirus and human enzymes ([**Fig. 3**](#f0003){ref-type="fig"}).

Tgs1/Tgs2 {#s0001-0004}
---------

The enzyme responsible for the trimethylguanosine (m^2,2,7^G, TMG) synthesis was first identified in yeast and named yTgs1.[@cit0064] The Tgs enzymes of budding and fission yeast and *Giardia* are relatively small polypeptides (239--315 amino acids) consisting of little more than an RFM methyltransferase catalytic domain ([**Fig. 4**](#f0004){ref-type="fig"}), whereas metazoan Tgs1 proteins are much larger, because they include an N-terminal extension not found in lower eukaryotes.[@cit0065] Tgs1 activity is strictly dependent on prior cap0 (m^7^G) methylation, thereby restricting its activity to RNAs that were already methylated by cap0 methyltransferase.[@cit0067] Similar substrate requirements are characteristic for the *Giardia* Tgs2 enzyme.[@cit0068] Interestingly, in contrast to Tgs1 methyltransferases able to catalyze 2 sequential N2 methylation steps leading to TMG cap formation, Tgs2 activity is apparently limited to a single round of N2 methylation, resulting in the synthesis of a 2,7-dimethylguanosine (m^2,7^G) product. Bioinformatics analyses predicted that the Tgs enzymes are related to a large group of RFM enzymes that act on exocyclic amine groups in nucleic acid bases, including m^6^A, m^4^C, and m^2^G and have a characteristic NPPY-like motif at the active site.[@cit0066] The crystal structure of the active C-terminal methyltransferase domain of the human TGS enzyme bound to a minimal substrate m^7^GTP as well as the reaction product SAH has been reported, confirming these predictions and revealing the atomic details of these protein-ligand interactions.[@cit0069] Figure 4.**Crystal structure of the human TGS1 protein.** Trimethylguanosine synthase catalyzes hypermethylation of cap0 structure. In a 2-step reaction, 2 methyl groups are transferred to the amine group of m^7^G and, as a result, the m^2,2,7^G structure is formed. The crystal structure of human TGS1 methyltransferase in complex with m^7^Gppp and SAH (shown in stick representation) is deposited in the PDB as 3GDH. Secondary structure elements that correspond to elements of the conserved RFM core are labeled. Secondary structure elements outside of the conserved core are not labeled.

Other methyltransferases involved in cap-specific base modifications {#s0001-0005}
--------------------------------------------------------------------

Studies of cap composition of human mRNAs conducted in mid-70s revealed that when the first nucleotide of the transcript is an adenosine, this base can be methylated to m^6^A.[@cit0008] The enzyme that catalyzes the conversion of m^7^GpppAm ends of mRNA to m^7^Gpppm^6^Am has been isolated from a cytoplasmic fraction of HeLa cells. The isolated enzyme showed no activity toward internal adenosines.[@cit0072] Recently, Schwartz and coworkers studied the m^6^A mRNA methylome following depletion of multiprotein methyltransferase complex components METTL3, METTL14, KIAA1429, and WTAP, and implicated the involvement of the METTL3, METTL14, and KIAA1429 proteins in m^6^A formation at the internal sites but not at the 5′ sites.[@cit0073] The full characterization of the cap-specific m^6^A methyltransferase activity requires further studies in vitro.

In trypanosomes, the first adenine of the hypermethylated cap4 structure is not only methylated at the ribose, but also dimethylated at the *N*^6^ position, to form m^6,6^Am. The methyltransferase responsible for the latter reaction remains unknown.[@cit0011] Further, the fourth uracil in that structure is modified to m^3^U, and the enzyme responsible for this modification also remains unknown.

Bin3/γ--methyltransferases {#s0001-0006}
--------------------------

The γ-methylphosphate cap structure is unique in that it is an alternative to the guanosine-containing cap. It is formed by a single methyltransfer reaction to a γ -phosphate oxygen at the 5′ end of the primary transcripts of certain small RNA molecules such as mammalian U6 and 7SK, mouse B2 and plant U3.[@cit0074] The enzyme responsible for this reaction, Bicoid-interacting protein 3 (Bin3), is a methyltransferase conserved in eukaryotes. It is, however, absent from *S. cerevisiae*.[@cit0075] A structure of the human Bin3 homolog (BCDIN3) was determined, revealing a conserved RFM core ([**Fig. 5**](#f0005){ref-type="fig"}). An enzyme-substrate complex is not yet available, and the details of protein-RNA recognition and the mechanism of discrimination between Bin3 substrates and non-substrates remain to be determined. Figure 5.**Crystal structure of human BCDIN3 γ-methyltransferase**. A stick representation of SAM as a donor of the methyl group which is transferred by the BCDIN3 (PDB ID: 3G07) enzyme on the 5′ γ-phosphate group of the 7SK snRNA molecule. Secondary structure elements that correspond to elements of the conserved RFM core are labeled (β5 is hidden behind α5 and therefore its label has been omitted). Secondary structure elements outside of the conserved core are not labeled.

Conclusions and Future Perspectives {#s0002}
===================================

In recent years significant progress has been made in understanding the mechanism of formation of different RNA cap structures. This progress has been driven in particular by the identification and characterization of novel methyltransferases that take part in cap biosynthesis, and by the determination of their crystal structures. This knowledge also has a practical dimension, as the capping process is essential for eukaryotic cells as well as for the life cycle of viruses that infect them. In this context, the difference between the structures of the human enzymes and the enzymes from human pathogens could be exploited to develop new drugs. In particular, viruses that evolved alternative enzymes to synthesize the same cap structures as are synthesized by human cellular machinery are attractive targets for the development of inhibitors that could specifically block viral methyltransferases.

To date, numerous high-resolution structures of viral RNA capping enzymes have been determined, in particular for cap methyltransferases from various flaviviruses, which have been considered an attractive new antiviral target.[@cit0077] Based on knowledge of structures, efforts have been made toward the identification of specific inhibitors of these enzymes. For instance, a structure-based search for new inhibitors was performed for the dengue virus methyltransferase.[@cit0078] The development of compounds that specifically inhibit viral methyltransferases will be aided by the recent structure determination of the catalytic domain of the human cap1 methyltransferase, which shares the global architecture, but exhibits a different cap-binding site compared to the viral enzymes.[@cit0039] The human cap1 methyltransferase appears to be essential and cannot be knocked out in human cells (our unpublished data), therefore the development of inhibitors specific against that human enzyme could be also useful as tools to study the cellular function of cap1 methylation.

The study on the process of SL RNA maturation in trypanosomal parasites could benefit from structure analysis of trypanosomal methyltransferases. While the cap0 and cap1 methyltransferases in trypanosomes are relatively closely related to their human counterparts, bioinformatics analyses identified cap2 and cap3/4 methyltransferases as close homologs of the vaccinia virus cap1 methyltransferase. While the analysis of protein-RNA interactions and search for potential regulatory molecules (e.g., inhibitors) could be guided by homology models developed so far,[@cit0047] experimental determination of high resolution structures for cap methyltransferases in trypanosomes would be definitely useful.

A complete understanding of RNA cap biosynthesis requires not only structure determination of the enzymes that are well characterized biochemically, but also the identification of the genes and proteins that encode the cap methylation machinery. Some of the prominent enzymatic activities known to exist that are still awaiting unequivocal identification of the corresponding proteins include m^6^A methylation of the first transcribed nucleoside of capped RNAs in humans, and m^6,6^A and m^3^U methylation of the first and the fourth residues in the cap4 structure in capped RNAs in trypanosomes. A comprehensive biochemical and structural characterization of these enzymes could further contribute to the possibility of developing new drugs against trypanosomal parasites and new tools to study RNA metabolism in human cells.

Disclosure of Potential Conflicts of Interest {#s0003}
=============================================

No potential conflicts of interest were disclosed.

Funding
=======

This analysis was supported in part by the Foundation for Polish Science (FNP, grant TEAM/2009-4/2 to J.M.B.). M.B. and E.P. were additionally supported by National Science Center (NCN, 2011/03/D/NZ1/03247 to E.P.). M.Ś. was additionally supported by the START Fellowship from the FNP. J.M.B. was additionally supported by the European Research Council (ERC, StG grant RNA^+^P = 123D) and by the \"Ideas for Poland\" fellowship from the FNP. Research on structural aspects of protein-RNA interactions in the Bujnicki laboratory has been also supported by grants from the European Union\'s Seventh Framework Program (REGPOT grant FishMed; grant agreement n° 316125), the Polish Ministry of Science and Higher Education (MNiSW, grant POIG.02.03.00-00-003/09) and by the infrastructure financed by the European Union---the European Regional Development Fund within the Operational Program "Innovative economy" for 2007--2013 (CePT, grant POIG.02.02.00-14-024/08-00).

[^1]: These authors contributed equally to the work.
